Genome instability footprint under rapamycin and hydroxyurea treatments.


Journal

PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 04 10 2023
accepted: 10 10 2023
revised: 16 11 2023
medline: 27 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: epublish

Résumé

The mutational processes dictating the accumulation of mutations in genomes are shaped by genetic background, environment and their interactions. Accurate quantification of mutation rates and spectra under drugs has important implications in disease treatment. Here, we used whole-genome sequencing and time-resolved growth phenotyping of yeast mutation accumulation lines to give a detailed view of the mutagenic effects of rapamycin and hydroxyurea on the genome and cell growth. Mutation rates depended on the genetic backgrounds but were only marginally affected by rapamycin. As a remarkable exception, rapamycin treatment was associated with frequent chromosome XII amplifications, which compensated for rapamycin induced rDNA repeat contraction on this chromosome and served to maintain rDNA content homeostasis and fitness. In hydroxyurea, a wide range of mutation rates were elevated regardless of the genetic backgrounds, with a particularly high occurrence of aneuploidy that associated with dramatic fitness loss. Hydroxyurea also induced a high T-to-G and low C-to-A transversion rate that reversed the common G/C-to-A/T bias in yeast and gave rise to a broad range of structural variants, including mtDNA deletions. The hydroxyurea mutation footprint was consistent with the activation of error-prone DNA polymerase activities and non-homologues end joining repair pathways. Taken together, our study provides an in-depth view of mutation rates and signatures in rapamycin and hydroxyurea and their impact on cell fitness, which brings insights for assessing their chronic effects on genome integrity.

Identifiants

pubmed: 37931001
doi: 10.1371/journal.pgen.1011012
pii: PGENETICS-D-23-00878
pmc: PMC10653606
doi:

Substances chimiques

Hydroxyurea X6Q56QN5QC
Sirolimus W36ZG6FT64
DNA, Ribosomal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1011012

Informations de copyright

Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12466-12471
pubmed: 29109257
Mol Biol Evol. 2014 Dec;31(12):3228-39
pubmed: 25172959
Nature. 2008 Jul 24;454(7203):479-85
pubmed: 18615017
Mol Biol Evol. 2019 Apr 1;36(4):691-708
pubmed: 30657986
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1897-902
pubmed: 24449905
Mol Cell. 2018 Nov 1;72(3):583-593.e4
pubmed: 30293780
Cancer Res. 2013 Jun 1;73(11):3393-401
pubmed: 23633493
Nature. 2018 Apr;556(7701):339-344
pubmed: 29643504
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28191-28200
pubmed: 33106417
Nat Commun. 2020 Jul 21;11(1):3664
pubmed: 32694532
G3 (Bethesda). 2016 Sep 08;6(9):3003-14
pubmed: 27371952
Mol Cell. 2010 Feb 26;37(4):492-502
pubmed: 20188668
G3 (Bethesda). 2015 Sep 02;5(11):2323-7
pubmed: 26338660
Bioinformatics. 2016 Jan 15;32(2):289-91
pubmed: 26424858
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9674-9
pubmed: 26195783
Mol Biol Evol. 2019 Dec 1;36(12):2861-2877
pubmed: 31397846
Nature. 2013 Aug 29;500(7464):571-4
pubmed: 23873039
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Genetics. 2008 Jan;178(1):67-82
pubmed: 18202359
Curr Genet. 1985;9(7):553-60
pubmed: 2836093
PLoS Genet. 2014 Dec 18;10(12):e1004894
pubmed: 25521586
J Biol Chem. 2004 Jan 2;279(1):223-30
pubmed: 14573610
Mol Biol Evol. 2017 Jul 1;34(7):1596-1612
pubmed: 28369610
Elife. 2021 Sep 15;10:
pubmed: 34523420
Genetics. 2013 Nov;195(3):1141-55
pubmed: 24037264
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9272-7
pubmed: 18583475
Curr Biol. 2019 May 20;29(10):1584-1591.e3
pubmed: 31056389
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5046-E5055
pubmed: 29760081
Cell Rep. 2017 Oct 17;21(3):732-744
pubmed: 29045840
Cell. 2011 Mar 4;144(5):719-31
pubmed: 21376234
BMC Genomics. 2019 Jul 12;20(1):579
pubmed: 31299901
Bioinformatics. 2020 May 1;36(10):3242-3243
pubmed: 32096823
Nat Commun. 2015 Aug 13;6:7972
pubmed: 26268986
Nature. 2019 Sep;573(7774):416-420
pubmed: 31511699
Mutat Res. 2021 Jan-Jun;822:111738
pubmed: 33578051
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):763-8
pubmed: 24347643
Nat Protoc. 2018 Jun;13(6):1213-1231
pubmed: 29725120
Genetics. 2011 Dec;189(4):1177-201
pubmed: 22174183
Genetics. 2019 Feb;211(2):731-740
pubmed: 30504363
Nat Commun. 2020 May 1;11(1):2169
pubmed: 32358516
Nature. 2015 Mar 12;519(7542):181-6
pubmed: 25731169
Nat Rev Cancer. 2021 Oct;21(10):619-637
pubmed: 34316057
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Nucleic Acids Res. 2021 Apr 19;49(7):3919-3931
pubmed: 33764464
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8114-E8121
pubmed: 27911848
Genetics. 2014 Nov;198(3):795-835
pubmed: 25381364
Genome Biol. 2016 May 09;17:99
pubmed: 27161042
Genome Res. 2014 Nov;24(11):1751-64
pubmed: 25217194
Cell. 2013 Jan 31;152(3):620-32
pubmed: 23352430
G3 (Bethesda). 2020 Dec 3;10(12):4637-4648
pubmed: 33093184
Cell. 2019 May 2;177(4):821-836.e16
pubmed: 30982602
Nucleic Acids Res. 2011 Mar;39(4):1336-50
pubmed: 20947565
EMBO J. 2001 Jul 16;20(14):3861-70
pubmed: 11447127
BMC Genomics. 2022 Feb 15;23(1):134
pubmed: 35168570
Annu Rev Pathol. 2016 May 23;11:283-312
pubmed: 26907526
BMC Biol. 2020 May 11;18(1):49
pubmed: 32393264
Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2310-8
pubmed: 24847077
Cell. 2005 Mar 11;120(5):587-98
pubmed: 15766523
Bioinformatics. 2021 Jul 19;37(12):1639-1643
pubmed: 33320174
Nature. 2012 Jan 29;482(7384):246-50
pubmed: 22286062
Nat Genet. 2019 Dec;51(12):1732-1740
pubmed: 31740835
Elife. 2022 Jul 08;11:
pubmed: 35801695
Genetics. 2020 Sep;216(1):43-50
pubmed: 32753390
Nat Genet. 2017 Jun;49(6):913-924
pubmed: 28416820
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24947-24956
pubmed: 32968016
Nature. 2020 Nov;587(7834):420-425
pubmed: 33177709
Genome Res. 2019 Oct;29(10):1685-1692
pubmed: 31548357
PLoS Genet. 2013;9(8):e1003680
pubmed: 23935537

Auteurs

Jing Li (J)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.

Simon Stenberg (S)

Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.

Jia-Xing Yue (JX)

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.

Ekaterina Mikhalev (E)

Ginkgo Bioworks, Boston, Massachusetts, United States of America.

Dawn Thompson (D)

Ginkgo Bioworks, Boston, Massachusetts, United States of America.

Jonas Warringer (J)

Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.

Gianni Liti (G)

Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH